Ranbezolid

Ranbezolid
Clinical data
Other names	RBX-7644
Identifiers
	IUPAC name N-{[(5S)-3-(3-Fluoro-4-{4-[(5-nitro-2-furyl)methyl]-1-piperazinyl}phenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide;
PubChemCID	496993;
ChemSpider	435159;
ChEMBL	ChEMBL251384;
CompTox Dashboard(EPA)	DTXSID701029733;
Chemical and physical data
Formula	C21H24FN5O6
Molar mass	461.450g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(=O)NC[C@H]1CN(C(=O)O1)c2ccc(N3CCN(Cc4oc(cc4)[N+](=O)[O-])CC3)c(F)c2;
	InChI InChI=1S/C21H24FN5O6/c1-14(28)23-11-17-13-26(21(29)33-17)15-2-4-19(18(22)10-15)25-8-6-24(7-9-25)12-16-3-5-20(32-16)27(30)31/h2-5,10,17H,6-9,11-13H2,1H3,(H,23,28)/t17-/m0/s1;

Ranbezolid(RBx7644) is anoxazolidinone antibacterial.It competitively inhibitsmonoamine oxidase-A(MAO-A).^[1]

References[edit]

^Naruganahalli KS, Shirumalla RK, Bansal V, Gupta JB, Das B, Ray A (September 2006). "Ranbezolid, a novel oxazolidinone antibacterial: in vivo characterisation of monoamine oxidase inhibitory potential in conscious rats".European Journal of Pharmacology.545(2–3): 167–72.doi:10.1016/j.ejphar.2006.06.065.PMID 16899241.

This systemicantibiotic-related article is astub.You can help Wikipedia byexpanding it.